Posted by Michael Wonder on 03 Oct 2024
Volastra Therapeutics granted FDA fast track designation for novel KIF18A inhibitor in ovarian cancer
2 October 2024 - Volastra Therapeutics today announced that the US FDA has granted fast track designation to VLS-1488, the company’s internally discovered KIF18A inhibitor.
The designation has been granted for the treatment of patients with platinum-resistant high-grade serous ovarian cancer.
